/
RUBY
$0.06+$0.00 (+2.70%)prev close
Change$-20.24
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on developing innovative red cell therapeutics (RCTs) to combat severe diseases. Its pipeline features RTX-240 and RTX-224, both advancing as treatments for solid tumor cancers, alongside RTX-aAPC for various other oncological conditions. The company is also progressing RTX-321 for HPV-positive tumors and RTX-T1D for the management of type 1 diabetes. Founded in 2013, Rubius Therapeutics is headquartered in Cambridge, Massachusetts.
www.rubiustx.com- Employees
- 6
- IPO / List date
- Jul 18, 2018
- HQ
- US
Held by traders on TradeandTell
No one on the platform currently holds RUBY.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in RUBY as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded RUBY yet.
